Health Catalyst, Inc. (HCAT)
NASDAQ: HCAT · Real-Time Price · USD
1.110
+0.015 (1.37%)
Mar 25, 2026, 11:37 AM EDT - Market open
Health Catalyst Stock Forecast
Stock Price Forecast
The 9 analysts that cover Health Catalyst stock have a consensus rating of "Hold" and an average price target of $2.53, which forecasts a 127.93% increase in the stock price over the next year. The lowest target is $1.00 and the highest is $4.00.
Price Target: $2.53 (+127.93%)
Analyst Consensus: Hold
Analyst Ratings
The average analyst rating for Health Catalyst stock is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 2 | 2 | 2 | 2 | 2 | 1 |
| Hold | 8 | 8 | 8 | 8 | 8 | 8 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 11 | 11 | 11 | 11 | 11 | 10 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Wells Fargo | Wells Fargo | Buy → Hold Downgrades $5 → $1 | Buy → Hold | Downgrades | $5 → $1 | -9.91% | Mar 18, 2026 |
| Citigroup | Citigroup | Hold Maintains $2.75 → $1.75 | Hold | Maintains | $2.75 → $1.75 | +57.66% | Mar 13, 2026 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $5 → $2 | Strong Buy | Maintains | $5 → $2 | +80.18% | Mar 13, 2026 |
| Stephens & Co. | Stephens & Co. | Hold Maintains $3.5 → $2 | Hold | Maintains | $3.5 → $2 | +80.18% | Mar 13, 2026 |
| Stifel | Stifel | Hold Maintains $3.75 → $2 | Hold | Maintains | $3.75 → $2 | +80.18% | Mar 13, 2026 |
Financial Forecast
Revenue This Year
289.67M
from 311.14M
Decreased by -6.90%
Revenue Next Year
290.80M
from 289.67M
Increased by 0.39%
EPS This Year
0.36
from -2.55
EPS Next Year
0.44
from 0.36
Increased by 20.70%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 313.9M | 323.1M | |
| Avg | 289.7M | 290.8M | |
| Low | 261.8M | 236.1M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 0.9% | 11.5% | |
| Avg | -6.9% | 0.4% | |
| Low | -15.9% | -18.5% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 0.65 | 0.72 | |
| Avg | 0.36 | 0.44 | |
| Low | 0.17 | 0.21 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | 98.6% | |
| Avg | - | 20.7% | |
| Low | - | -43.6% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.